Quetiapine : A review of its use in acute mania and depression associated with bipolar disorder
Quetiapine (Seroquel), an atypical antipsychotic with established efficacy in the treatment of schizophrenia, shows efficacy in the treatment of acute mania and depression associated with bipolar disorder.Quetiapine, either as monotherapy or in combination with lithium or divalproex sodium (valproat...
Gespeichert in:
| Veröffentlicht in: | Drugs (New York, N.Y.) N.Y.), 2005-01, Vol.65 (17), p.2533-2551 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2551 |
|---|---|
| container_issue | 17 |
| container_start_page | 2533 |
| container_title | Drugs (New York, N.Y.) |
| container_volume | 65 |
| creator | DANDO, Toni M KEATING, Gillian M |
| description | Quetiapine (Seroquel), an atypical antipsychotic with established efficacy in the treatment of schizophrenia, shows efficacy in the treatment of acute mania and depression associated with bipolar disorder.Quetiapine, either as monotherapy or in combination with lithium or divalproex sodium (valproate semisodium), is generally well tolerated and effective in reducing manic symptoms in adult and adolescent patients with acute bipolar mania, and is approved for use in adults for this indication. As monotherapy, the drug is also effective in reducing depressive symptoms in patients with bipolar depression. It is associated with a low incidence of extrapyramidal symptom (EPS)-related adverse events and low EPS ratings in bipolar disorder. Quetiapine thus shows potential in the treatment of bipolar depression, and represents a useful agent for the treatment of acute bipolar mania. |
| doi_str_mv | 10.2165/00003495-200565170-00008 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_cross</sourceid><recordid>TN_cdi_gale_infotracmisc_A200669351</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A200669351</galeid><sourcerecordid>A200669351</sourcerecordid><originalsourceid>FETCH-LOGICAL-c355t-af0e3db9441751568263d7a02879073bcdf7202f955d4561ddc4fe0be7097b2d3</originalsourceid><addsrcrecordid>eNptkMlKBDEURbNQnH9BAuKy2gyVpOKuEScQRNB1kUpe9EnXQFKt-PdW260imCxC7rvnLQ4hlLOZ4FqdsenI0qpCMKa04oYVq6jaInuMcVForc0u2c_5dfW1yu6QXa6F1ZXRe6R-WMKIbsAO6Dmd0wRvCO-0jxTHTJcZKHbU-eUItHUdOuq6QAMMCXLGfhrl3Ht0IwT6juMLbXDoFy7RgLlPAdIh2Y5ukeFo8x6Qp6vLx4ub4u7--vZifld4qdRYuMhAhsaWJTeKK10JLYNxTFTGMiMbH6IRTESrVCiV5iH4MgJrwDBrGhHkATlZ7312C6ixi_2YnG8x-3o-idHaSsWn1uyf1nQDtOj7DiJO-R-gWgM-9TkniPWQsHXpo-asXumvv_XXP_q_ompCj9fosGxaCL_gxv1UON0UXPZuEZPrPObfnpGlLhmXnzeojV8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Quetiapine : A review of its use in acute mania and depression associated with bipolar disorder</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>DANDO, Toni M ; KEATING, Gillian M</creator><creatorcontrib>DANDO, Toni M ; KEATING, Gillian M</creatorcontrib><description>Quetiapine (Seroquel), an atypical antipsychotic with established efficacy in the treatment of schizophrenia, shows efficacy in the treatment of acute mania and depression associated with bipolar disorder.Quetiapine, either as monotherapy or in combination with lithium or divalproex sodium (valproate semisodium), is generally well tolerated and effective in reducing manic symptoms in adult and adolescent patients with acute bipolar mania, and is approved for use in adults for this indication. As monotherapy, the drug is also effective in reducing depressive symptoms in patients with bipolar depression. It is associated with a low incidence of extrapyramidal symptom (EPS)-related adverse events and low EPS ratings in bipolar disorder. Quetiapine thus shows potential in the treatment of bipolar depression, and represents a useful agent for the treatment of acute bipolar mania.</description><identifier>ISSN: 0012-6667</identifier><identifier>DOI: 10.2165/00003495-200565170-00008</identifier><identifier>PMID: 16296876</identifier><identifier>CODEN: DRUGAY</identifier><language>eng</language><publisher>Auckland: Adis International</publisher><subject>Antipsychotic Agents - adverse effects ; Antipsychotic Agents - pharmacology ; Antipsychotic Agents - therapeutic use ; Biological and medical sciences ; Bipolar Disorder - drug therapy ; Depression - drug therapy ; Dibenzothiazepines - adverse effects ; Dibenzothiazepines - pharmacology ; Dibenzothiazepines - therapeutic use ; Humans ; Medical sciences ; Neuropharmacology ; Pharmacology. Drug treatments ; Psycholeptics: tranquillizer, neuroleptic ; Psychology. Psychoanalysis. Psychiatry ; Psychopharmacology ; Quetiapine Fumarate ; Randomized Controlled Trials as Topic</subject><ispartof>Drugs (New York, N.Y.), 2005-01, Vol.65 (17), p.2533-2551</ispartof><rights>2006 INIST-CNRS</rights><rights>COPYRIGHT 2005 Wolters Kluwer Health, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c355t-af0e3db9441751568263d7a02879073bcdf7202f955d4561ddc4fe0be7097b2d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17346401$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16296876$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>DANDO, Toni M</creatorcontrib><creatorcontrib>KEATING, Gillian M</creatorcontrib><title>Quetiapine : A review of its use in acute mania and depression associated with bipolar disorder</title><title>Drugs (New York, N.Y.)</title><addtitle>Drugs</addtitle><description>Quetiapine (Seroquel), an atypical antipsychotic with established efficacy in the treatment of schizophrenia, shows efficacy in the treatment of acute mania and depression associated with bipolar disorder.Quetiapine, either as monotherapy or in combination with lithium or divalproex sodium (valproate semisodium), is generally well tolerated and effective in reducing manic symptoms in adult and adolescent patients with acute bipolar mania, and is approved for use in adults for this indication. As monotherapy, the drug is also effective in reducing depressive symptoms in patients with bipolar depression. It is associated with a low incidence of extrapyramidal symptom (EPS)-related adverse events and low EPS ratings in bipolar disorder. Quetiapine thus shows potential in the treatment of bipolar depression, and represents a useful agent for the treatment of acute bipolar mania.</description><subject>Antipsychotic Agents - adverse effects</subject><subject>Antipsychotic Agents - pharmacology</subject><subject>Antipsychotic Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Bipolar Disorder - drug therapy</subject><subject>Depression - drug therapy</subject><subject>Dibenzothiazepines - adverse effects</subject><subject>Dibenzothiazepines - pharmacology</subject><subject>Dibenzothiazepines - therapeutic use</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Neuropharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Psycholeptics: tranquillizer, neuroleptic</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Quetiapine Fumarate</subject><subject>Randomized Controlled Trials as Topic</subject><issn>0012-6667</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptkMlKBDEURbNQnH9BAuKy2gyVpOKuEScQRNB1kUpe9EnXQFKt-PdW260imCxC7rvnLQ4hlLOZ4FqdsenI0qpCMKa04oYVq6jaInuMcVForc0u2c_5dfW1yu6QXa6F1ZXRe6R-WMKIbsAO6Dmd0wRvCO-0jxTHTJcZKHbU-eUItHUdOuq6QAMMCXLGfhrl3Ht0IwT6juMLbXDoFy7RgLlPAdIh2Y5ukeFo8x6Qp6vLx4ub4u7--vZifld4qdRYuMhAhsaWJTeKK10JLYNxTFTGMiMbH6IRTESrVCiV5iH4MgJrwDBrGhHkATlZ7312C6ixi_2YnG8x-3o-idHaSsWn1uyf1nQDtOj7DiJO-R-gWgM-9TkniPWQsHXpo-asXumvv_XXP_q_ompCj9fosGxaCL_gxv1UON0UXPZuEZPrPObfnpGlLhmXnzeojV8</recordid><startdate>20050101</startdate><enddate>20050101</enddate><creator>DANDO, Toni M</creator><creator>KEATING, Gillian M</creator><general>Adis International</general><general>Wolters Kluwer Health, Inc</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20050101</creationdate><title>Quetiapine : A review of its use in acute mania and depression associated with bipolar disorder</title><author>DANDO, Toni M ; KEATING, Gillian M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c355t-af0e3db9441751568263d7a02879073bcdf7202f955d4561ddc4fe0be7097b2d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Antipsychotic Agents - adverse effects</topic><topic>Antipsychotic Agents - pharmacology</topic><topic>Antipsychotic Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Bipolar Disorder - drug therapy</topic><topic>Depression - drug therapy</topic><topic>Dibenzothiazepines - adverse effects</topic><topic>Dibenzothiazepines - pharmacology</topic><topic>Dibenzothiazepines - therapeutic use</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Neuropharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Psycholeptics: tranquillizer, neuroleptic</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Quetiapine Fumarate</topic><topic>Randomized Controlled Trials as Topic</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>DANDO, Toni M</creatorcontrib><creatorcontrib>KEATING, Gillian M</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Drugs (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>DANDO, Toni M</au><au>KEATING, Gillian M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Quetiapine : A review of its use in acute mania and depression associated with bipolar disorder</atitle><jtitle>Drugs (New York, N.Y.)</jtitle><addtitle>Drugs</addtitle><date>2005-01-01</date><risdate>2005</risdate><volume>65</volume><issue>17</issue><spage>2533</spage><epage>2551</epage><pages>2533-2551</pages><issn>0012-6667</issn><coden>DRUGAY</coden><abstract>Quetiapine (Seroquel), an atypical antipsychotic with established efficacy in the treatment of schizophrenia, shows efficacy in the treatment of acute mania and depression associated with bipolar disorder.Quetiapine, either as monotherapy or in combination with lithium or divalproex sodium (valproate semisodium), is generally well tolerated and effective in reducing manic symptoms in adult and adolescent patients with acute bipolar mania, and is approved for use in adults for this indication. As monotherapy, the drug is also effective in reducing depressive symptoms in patients with bipolar depression. It is associated with a low incidence of extrapyramidal symptom (EPS)-related adverse events and low EPS ratings in bipolar disorder. Quetiapine thus shows potential in the treatment of bipolar depression, and represents a useful agent for the treatment of acute bipolar mania.</abstract><cop>Auckland</cop><pub>Adis International</pub><pmid>16296876</pmid><doi>10.2165/00003495-200565170-00008</doi><tpages>19</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0012-6667 |
| ispartof | Drugs (New York, N.Y.), 2005-01, Vol.65 (17), p.2533-2551 |
| issn | 0012-6667 |
| language | eng |
| recordid | cdi_gale_infotracmisc_A200669351 |
| source | MEDLINE; SpringerNature Journals |
| subjects | Antipsychotic Agents - adverse effects Antipsychotic Agents - pharmacology Antipsychotic Agents - therapeutic use Biological and medical sciences Bipolar Disorder - drug therapy Depression - drug therapy Dibenzothiazepines - adverse effects Dibenzothiazepines - pharmacology Dibenzothiazepines - therapeutic use Humans Medical sciences Neuropharmacology Pharmacology. Drug treatments Psycholeptics: tranquillizer, neuroleptic Psychology. Psychoanalysis. Psychiatry Psychopharmacology Quetiapine Fumarate Randomized Controlled Trials as Topic |
| title | Quetiapine : A review of its use in acute mania and depression associated with bipolar disorder |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T09%3A12%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Quetiapine%20:%20A%20review%20of%20its%20use%20in%20acute%20mania%20and%20depression%20associated%20with%20bipolar%20disorder&rft.jtitle=Drugs%20(New%20York,%20N.Y.)&rft.au=DANDO,%20Toni%20M&rft.date=2005-01-01&rft.volume=65&rft.issue=17&rft.spage=2533&rft.epage=2551&rft.pages=2533-2551&rft.issn=0012-6667&rft.coden=DRUGAY&rft_id=info:doi/10.2165/00003495-200565170-00008&rft_dat=%3Cgale_cross%3EA200669351%3C/gale_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/16296876&rft_galeid=A200669351&rfr_iscdi=true |